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Background: The inevitable side effects of the currently used chemotherapy are associated with serious
syndromes. Genotoxic effects and consequent genetic instability may play an important role in these syndromes.
The aim of the study was to evaluate chemotherapy-related microsatellite instability (MSI), loss of heterozygosity
(LOH), and loss of mismatch repair (MMR) expression in solid tumor patients.
Methods: Samples were collected from 117 de novo patients with solid tumors of different origins. Specimens,
taken pre- and post-treatment, were screened for MSI and LOH in 10 microsatellite sequences in blood, and
expression of five MMR proteins were analyzed in cancer tissues using immunohistochemistry. Statistical analysis
included the use of; Fisher’s exact test, Chi Square, and an inter-rater reliability test using Cohen’s kappa coefficient.
Results: Microsatellite analysis showed that 66.7% of the patients had MSI, including 23.1% high-positive MSI and
43.6% low-positive MSI. A large portion (41%) of the patients exhibited LOH in addition to MSI. MSI and LOH were
detected in seven loci in which incidence rates ranged from 3.8% positive for Bat-26 to 34.6% positive for Tp53-Alu.
Immunohistochemistry revealed that human mutL homolog 1 (hMLH1) expression was deficient in 29.1% of the
patients, whereas 18.8%, 23.9%, 13.4%, and 9.7% were deficient for human mutS homolog 2 (hMSH2), P53, human
mutS homolog 6 (hMSH6) and human post-meiotic segregation increased 2 (hPMS2), respectively. There was a
significant correlation between MSI and LOH incidence in Tp53-Alu, Mfd41, and APC with low or deficient expression
of hMLH1, hMSH2, and P53. A significant association between MSI and LOH, and incidence of secondary tumors was
also evident.
Conclusions: The negative correlation between MMR expression, MSI, and LOH and increased resistance to
anti-cancer drugs and development of secondary cancers demonstrates a useful aid in early detection of
potential chemotherapy-related side-effects. The diagnostic value demonstrated in our earlier study on breast
cancer patients was confirmed for other solid tumors.
Keyword: Chemotherapy, Genetic instability, Microsatellites, Mismatch repair, Secondary tumorsBackground
Genomic alterations in patients receiving chemotherapy,
especially alkylating agents, lead to many abnormal clin-
ical phenotypes. Increased resistance to chemotherapy
treatments and generation of secondary cancers, e.g. sec-
ondary acute myeloid leukemia (AML) and/or myelodys-
plasia have been reported with incidence rates of 1-5%* Correspondence: nasir.kamat@su.se
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unless otherwise stated.[1-4]. Chemotherapy-related AML was described in the
1980s [5,6], followed by a wider range of investigations
including all types of cytotoxic agents. In many cancer
patients, AML has been detected from a few months to
several years after chemotherapy treatment [2,3,5,7-10].
Genetic alterations that may be the cause of secondary
neoplasms include both germline and somatic muta-
tions, and one or more mechanisms (point mutations,
deletions, mitotic recombination, gene conversion, non-
disjunction and chromosomal loss, or rearrangement of
genes) can be implicated [11-13].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Incidences of MSI-L, MSI-H, and LOH in blood











Pre-treatment 117 0 0 0
Post-treatment 1 117 51 27 48
Post-treatment 2 117 30 0 48
Reference (healthy)
Pre-treatment 60 0 0 0
Post-treatment 1 60 2 0 0
Post-treatment 2 60 0 0 0
LOH at alleles 109 and 118 of APC was accompanied by the appearance of a
novel allele of 162 base pairs (see Additional file 1: Figure S1). Furthermore,
the incidence rate versus age correlation showed that the incidence of MSI/
LOH increased with age (see Additional file 2: Figure S2). Cancer-specific
incidences of instability showed that pancreatic, lung, and gastric cancer
patients had high incidences of MSI (Table 4).
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of arrays of one to five base pairs (i.e., microsatellites)
have been used as molecular biomarkers in kinship,
population genetics, linkage mapping, and other studies
[14-17]. These DNA sequences are particularly prone to
mutations generating new allele lengths via insertion–
deletion loop formation during DNA synthesis [18,19].
Microsatellites can also serve in studying lesions at the
gene level, such as duplication or deletion [20,21].
Microsatellite instability (MSI) and loss of heterozygosity
(LOH) are frequently described abnormalities known to
be some of the early steps in the tumorigenesis pathway
[22-24], and correction of MSI and LOH requires suffi-
cient expression and activity of MMR proteins [25].
Genetic alterations are normally corrected by the mis-
match repair system (MMR), which employs several
proteins including human mutL homolog 1 (hMLH1),
human mutS homolog 2, 3 and 6 (hMSH2, hMSH3, and
hMSH6, respectively), and human postmeiotic segrega-
tion increased1 and 2 (hPMS1 and hPMS2) that are
known to interact with P53 protein and tumor suppres-
sor genes [26-28]. Interaction between MMR and tumor
suppressor genes is an integral part of repairing damages
in microsatellite sequences and reducing potential car-
cinogenesis in affected patients [29,30]. However, when
affected alleles are within tumor suppressor genes, this
may lead to loss of function of an active tumor suppres-
sor protein [31,32], which indicates the necessity to as-
sess the genetic alterations within that gene. Moreover, a
study conducted in a murine model has demonstrated
the trans-generational nature of genotoxic effects of anti-
cancer drugs. The genetic alterations appeared with an in-
creased frequency in germline and somatic cells of the
first-generation offspring of the treated animals [33,34].
This trans-generational effect naturally raises concerns
about similar genetic instability in children of anticancer
therapy survivors.
Treatment-related MSI and LOH have been analyzed
in a few studies in recent years, highlighting the import-
ance of screening patients for these genomic instabilities
after chemotherapy completion [35-37]. Consequences
of MSI and LOH that were observed in these studies in-
cluded increased resistance to chemotherapy, recurrence
of primary tumors, and/or appearance of secondary
malignancies. However, these studies were exclusively
conducted on breast cancer patients. Investigating the
possibility of similar outcomes in patients with other
cancers is necessary to determine if this is a more wide-
spread phenomenon.
Following the results reported in our previous study
on breast cancer patients [37], a new study was similarly
designed to assess whether patients with other solid
tumors are predisposed to higher genetic instability linked
to chemotherapy treatment. In addition, the present studyincludes an extended follow-up period of 52 months to
verify if it is possible to correlate MSI, LOH, and reduced
MMR expression with clinical findings. We believe that
such results would point to the existence of a link between
chemotherapy-related genetic instability and clinical phe-




Screening of 10 microsatellite markers revealed that 78
of 117 solid tumor patients (66.7%) had microsatellite in-
stability in at least one locus. Based on National Cancer
Institute (NCI) criteria, 27 patients (23.1%) were found
to be high-positive MSI (MSI-H) due to MSI and LOH
in two or more microsatellites sequences, and 51 pa-
tients (43.6%) exhibited single MSI events and were clas-
sified as low-positive MSI (MSI-L). LOH was detected in
48 patients (41%). No MSI or LOH was detected in any
of the tested markers in 39 patients (33.3%); this group
was classified as microsatellite stable. No MSI or LOH
events were detected in the pre-treatment specimens
(Table 1). The total incidence of MSI in the blood
samples collected was 108/351 (30.7%). However, the
incidence decreased with time. MSI detected in post-
treatment specimens was reduced from 78 (66.6%) in
the first to 30 (25.4%) in the second post-treatment sam-
ples, and this is compatible with the transient nature of
MSI lesions. The number of LOH events, 48 giving a
total of 27.4%, was evenly distributed between the two
post-treatment groups (Table 1). Detailed individual inci-
dences of MSI and LOH (Table 2) showed that there
was a significant occurrence of these instabilities in five
of the seven markers. Tp53-Alu on chromosome 17 was
Table 2 Incidence rate of MSI and LOH, number of alleles isolated, and allelic imbalance noticed for each marker
Marker Chr./Locus No of positive patients % of positive MSI No. of alleles isolated Allelic imbalance
Mfd15 17q11.2 15 19.2% 7 L 0–0.69 U 1.56-2.72
APC 5q21/22 17 21.8% 8 L 0–0.69 U 1.5-2.61
Tp53-Alu 17p13.1 27 34.6% 12 L 0–0.67 U 1.48-2.53
Mfd41 17p12-11.1 21 26.9% 8 L 0–0.59 U 1.35-2.76
Bat-25 4q12 0 0% 4 L 0.71-0.77 U 0.94-1.2
TP53.PCR15 17p13.1 0 0% 5 L 0.80-0.86 U 0.92-1.23
AFM093xh3 2p16 11 14.1% 6 L 0–0.68 U 1.51-2.44
Bat-40 1p13.1 0 0% 4 L 0.73-0.81 U 0.91-1.31
Bat-26 2p 3 3.8% 4 L 0.23-0.62 U 1.31-1.65
Mfd28 10pter 7 8.9% 5 L 0.2-0.64 U 1.37-1.95
L = lower allelic imbalance. U = upper allelic imbalance range.
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positive patients exhibited mutations in this locus. Less
frequent but significant incidences of MSI/LOH were
observed in Mfd41and Mfd15 on chromosome 17, APC
on chromosome 5, and AFM093xh3 on chromosome 2
(26.9%, 19.2%, 21.8%, and 14.5%, respectively, Table 2).
Alleles 399 and 402 of Tp53-Alu, allele 157 of Mfd41,Figure 1 Typical microsatellite instability (MSI) and loss of heterozygo
several patients. P## represent the patient’s number. Pre-T = pre-treatmen
the lesion in post-treatment analyses. In two of the LOH cases also new all
used to label overlapping markers (detailed markers characteristics includinallele 198 of AFM093xh3, alleles 147 and 152 of Mfd15,
and allele 109 of APC all demonstrated instability and
LOH more frequently than other alleles tested (Figure 1).
MSI appeared in Tp53-Alu as deletions or insertions of
one to a few base pairs, these events occurred with simi-
lar frequencies, indicating no inherent preference for
one event over the other. LOH formed the majority ofsity (LOH) in five microsatellites in post-treatment samples from
t specimen analysis, Pst-T = post-treatment analysis. Arrows point to
eles, representing simultaneous MSI, could be seen. Different dyes were
g used dyes are displayed in Additional file 3: Table S2.
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100% decrease in allele signal. Changes in Mfd41 in-
cluded shortening of the original allele peak height and
the addition of new peaks on both sides of the allele with
a higher tendency of deletions (i.e., shorter sequences).
LOH in alleles 109 and 118 of APC was accompanied by
the emergence of a novel allele of 162 nucleotides
(Additional file 1: Figure S1). A reference group of healthy
individuals was screened using the same microsatellites
panel. The results showed transient MSI-L in two individ-
uals; one in Mfd15 and the other in TP53.PCR15 loci
(Table 1). Both transient MSI-L events disappeared in the
second samples from the healthy individuals. No LOH
events were detected in the blood samples from the refer-
ence group.
Cancer tissues
Immunohistochemistry demonstrated that chemother-
apy treatment induced a loss of expression of MMR
proteins. In pre-treatment specimens, hMLH1was defi-
cient in 22 patients (22%), whereas in post-treatment
specimens hMLH1 found to be deficient in 51 patients
(51%), which indicate a loss of expression of this MMR
protein in 29% of cancer tissue (p <0.0001) after receiving
chemotherapy. Furthermore, the pre-treatment specimens
showed that hMSH2, P53, hMSH6, and hPMS2 were defi-
cient in 16, 27, 11, and 9 patients, whereas post-treatment
specimens were deficient in 35, 51, 25, and 19 patients,
respectively. These deficiencies accounted for 18.8%
(p <0.0001), 23.9% (p <0.0001), 13.4% (p = 0.0001),
and 10.2% (p <0.0001) in hMSH2, P53, hMSH6 and
hPMS2, respectively.Table 3 Correlation of MSI/LOH incidence to the low expressi
Mfd41 Tp5
hMLH1 Kappa −0.111 0.19
p-value 0.212 0.03
Significance Level Ns **
hMSH2 Kappa 0.761 0.77
p-value < 0.0001 < 0.
Significance level *** ***
P53 Kappa 0.139 0.55
p-value 0.129 < 0.
Significance level Ns ***
hMSH6 Kappa 0.023 0.10
p-value 0.503 0.41
Significance level Ns Ns
hPMS2 Kappa 0.142 −0.2
p-value 0.119 0.31
Significance level Ns Ns
**refers to moderately significant correlation.
***refers to highly significant correlation.Statistical analysis showed a significant correlation be-
tween low or deficient expression of hMSH2 and MSI/
LOH in Tp53-Alu, Mfd41, and APC (Table 3). Low P53
expression significantly correlated with MSI and LOH in
Tp53-Alu and APC, whereas low or deficient expression
of hMLH1 correlated with MSI and LOH in only Tp53-
Alu (Table 3). Clinical follow-up studies for up to
52 months revealed that 19 patients (16.2%) were diag-
nosed with clinical complications of increased resistance
to the applied chemotherapy; 15 patients (12.8%) had a
recurrence of primary tumors and 4 patients (3.4%)
developed secondary tumors (Table 4). All 19 compli-
cated cases were patients previously diagnosed to have
chemotherapy-related MSI and LOH after the comple-
tion of their treatment regimen (13 patients [11.1%] with
MSI-H and 6 [5.1%] with MSI-L). Fisher’s exact test in-
dicated a significant association between MSI/LOH and
the incidence of secondary tumors (two-sided Fisher’s
exact p = 0.018, and one-sided Fisher’s exact p = 0.012).
Discussion
The occurrence of chemotherapy-related genetic in-
stability, especially MSI and LOH, is documented in sev-
eral studies [38-40]. The importance of studying these
instabilities is emphasized by the role MSI and LOH play
in the early stages of tumorigenesis and cancer develop-
ment [22-24]. The assessment of MSI and LOH may
carry a predictive value for earlier detection and man-
agement of secondary tumors [37,41]. Since previous re-
ports indicate that the use of 10 markers is optimal, the
present study used a panel of five microsatellites recom-
mended by the NCI guidelines and another five markerson of MMR genes
3-alu Mfd15 APC AFM093xh3
8 −0.167 −0.046 −0.153
1 0.041 0.587 0.078
Ns Ns Ns
6 0.011 0.479 0.011
0001 0.899 < 0.0001 0.312
Ns *** Ns
9 −0.145 0.213 −0.125
0001 0.093 0.016 0.088
Ns ** Ns
1 −0.115 0.033 −0.178
3 0.121 0.311 0.052
Ns Ns Ns
06 −0.162 0.086 −0.107
2 0.241 0.311 0.189
Ns Ns Ns
Table 4 Cancer types specific results (ratio to the cohort, low and high-positive MSI in each type)
Cancer type No. of cases %: study cohort MSI- L MSI-H Recurrence Secondary CAs
Gastric CA 20 17.1% 11 6 4 1
Nasopharyngeal CA 19 16.2% 6 4 2 1
Ovary CA 13 11.1% 5 3 2 0
Lung CA 12 10.3% 7 3 3 1
Pancreas CA 9 7.7% 5 3 2 1
Squamous carcinoma 9 7.7% 5 1 0 0
Prostate CA 9 7.7% 3 0 0 0
Anal canal CA 6 5.1% 1 2 0 0
Germ cell tumor 6 5.1% 2 2 1 0
Oral cavity 4 3.4% 2 0 0 0
Uterus sarcoma 4 3.4% 2 0 0 0
Urinary bladder CA 3 2.6% 1 2 0 0
Glioblastoma CA 2 1.7% 1 0 0 0
Ewing sarcoma 1 0.9% 0 1 1 0
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including the present study, show varied incidences of
MSI and LOH in many types of cancers [45-47]. Our in-
vestigation revealed MSI and LOH mutations to occur
in 7/10 markers studied, a total MSI incidence of 66.7%
among mixed origin cancer patients represents a signifi-
cant level of chemotherapy related genetic instability.
MSI and LOH events appeared to be most prevalent
in the Tp53-Alu marker, although Mfd41 and APC also
exhibited significant incidences of MSI and LOH
(Table 2). These results do not seem to be due to spon-
taneous occurrence, given that the individuals in the
reference group did not show any changes in these
microsatellite sequences. In addition, MSI and LOH
events significantly correlated with low expression of
MMR proteins (Table 3). These findings support the
hypothesis that malfunctions of the MMR, along with
the error-prone nature of microsatellite sequences, con-
tributes to the development of MSI and LOH. Previous
studies report that chemotherapy-induced MSI and LOH
triggers secondary AML and myelodysplastic syndrome in
1-2% of cancer patients within a few months to several
years after completion of chemotherapy [1-3,7]. Recent
studies with larger cohorts and broader selection of tumor
types suggest an even higher incidence (up to 5%) of
secondary tumors [4]. Additionally, secondary AML is be-
lieved to occur in 10-30% of all diagnosed cases of AML
[3]. The elevated incidence of secondary AML in more re-
cent studies could be due to longer survival times for
chemotherapy treated patients, and the administration of
new generations of DNA-damaging chemotherapies (par-
ticularly alkylating agents and platinum-based anti-cancer
drugs). It is not yet fully understood if somatic mutations
predispose carriers to specific tumors, or at minimum,mediate the development of resistant phenotypes of
cancer.
In reviewing the incidence of MSI and LOH in differ-
ent solid tumors (Table 4), we observed that gastric,
lung, ovarian, nasopharyngeal, pancreatic, squamous cell
carcinoma, and prostate cancers (which together form
78% of our cohort) showed varied incidence of MSI. In-
cidence of MSI ranged from 33.3% in prostate to 83-87%
in lung, pancreatic and gastric cancers, and showed a
strong correlation with deficiencies of MMR proteins.
Follow-up studies for up to 52 months showed that un-
desirable effects of chemotherapy were detected in those
patients who previously were found to harbor MSI and
LOH mutations and show MMR deficiency. These ef-
fects are presented clinically as resistance to chemother-
apy regimen and recurrence of the primary disease in 15
patients (12.8%), or developing secondary cancers or
myelodysplastic syndrome in 4 patients (3.4%; Table 4). Pre-
vious studies have shown that although immunohistochem-
istry has an advantage over MSI analysis in identifying
MMR deficient samples, it is incapable of distinguishing
MMR proteins with impaired function from normally func-
tioning proteins [48,49]. The four major MMR proteins
(hMLH1, hMSH2, hMSH6, and hPMS2) are not equally
engaged in the repair of different length microsatellite in-
stability. hMSH6 is involved primarily in the repair of single
base-base mismatches or single base deletions/insertions,
but appears to have no functional role in the repair of
dinucleotides or longer mismatches [49]. This variety in
MMR protein roles highlights the necessity of combining
microsatellite instability analysis with MMR proteins im-
munohistochemistry in screening cancer patients.
LOH in tumor suppressor inhibitor of growth 1 (ING1)
is associated with carcinogenesis in human non-small cell
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(NF1) gene promotes formation of malignant melanoma
[51]. Our results add to this evidence by demonstrating
somatic mutations leading to LOH in another tumor sup-
pressor gene (Tp53-alu, chr. 17p13.1). Another important
finding of this study was the MSI and LOH observed in
APC; LOH in certain alleles of APC was accompanied
with the emergence of a novel allele at this locus. Whereas
APC plays a role in hereditary nonpolyposis colorectal
cancer (HNPCC) [52], and is methylated in the tumori-
genesis of other cancers [53,54], mutated APC may be of
value in predicting secondary malignancies if more data
are made available about its status during tumorigenesis
of secondary cancers.
A murine study designed to assess the profundity and
persistence of the genotoxic effects of chemotherapy
drugs in current use showed that chemotherapy drugs
pose a trans-generational risk manifested in higher mu-
tation rates and genetic instability in the first generation
of the treated animals [33,34]. These results may justify
concerns about similar genetic instabilities in children of
anticancer chemotherapy surviving patients.
Insertion/deletion mutations and the error-prone nature
of microsatellites are often implicated in the development
of chemotherapy-related secondary malignancies. Recent
findings suggest an involvement of myeloid/lymphoid or
mixed-lineage leukemia rearrangement events as a trigger-
ing mechanism that mediates the development of second-
ary AML after completion of chemotherapy treatment
using Etoposide [11], or a combination of Methotrexate,
Cisplatin, doxorubicin, and Etoposide [7].
A predictive value for MSI and LOH in HNPCC was
determined after use in molecular profiling and survival
studies in such patients [41,55]. Recent findings support
the role of somatic mutations in tumor suppressors in
cancers developing resistance to chemotherapies [56,57].
This may be explained by emphasizing the mode of ac-
tion of many chemotherapies; these treatments aim to
trigger programmed cell death in cancer cells, a process
largely mediated by tumor suppressors like the tumor
protein 53 (Tp53) and retinoblastoma (RB) genes. Ana-
lysis of MSI and LOH in sequences linked to these genes
is likely to be of predictive value in tumorigenesis that is
known to occur through inactivation of these genes.
Although our cohort was predominantly younger (68
patients less than 51 years of age, see Additional file 2:
Figure S2), our results indicate that MSI and LOH in-
creased with age, likely due to the synergistic effect
between chemotherapy-induced genetic instability and
age-related increased cellular stress.
MSI and LOH play an important role in the early
stages of tumorigenesis. The frequency with which MSI
and LOH present as adverse effects of currently used
chemotherapy drugs, along with the important roleLOH plays in inactivating tumor suppressor genes, dem-
onstrates the importance of MSI and LOH as indicators
and valuable bio-markers in screening cancer patients
after completion of their chemotherapy regimen. More-
over, screening of microsatellite sequences that are dir-
ectly related to tumor suppressors or are physically
adjacent to these genes may aid in the earlier prediction
of secondary neoplasm and is likely to provide a better
understanding of tumorigenesis, which in turn may lead
to more efficient alternative treatments.
Methods
Study design and chemotherapy regimen
The inclusion rule applied in this study was that only
patients receiving chemotherapy for the first time were
selected. Patients with colon or breast cancers and those
with family history or evidence of higher tendency to de-
velop tumors were excluded. Peripheral blood was col-
lected for genetic analysis and tumor tissues that were
biopsied or resected from patients were retrieved from
pathology departments to perform immunohistochemis-
try testing for the expression of MMR proteins. Follow-
up studies were performed for 48–52 months after com-
pletion of the chemotherapy regimen to monitor the
presence of clinical complications (especially resistance
to chemotherapy, recurrence of primary disease, and/or
development of secondary cancers).
Patients were monitored for chemotherapy-related
MSI and LOH, MMR expression, and tumor recurrences
or development of secondary tumors. Chemotherapy
regimens administered in the management of the tumors
that were sampled in this study are displayed in Additional
file 3: Table S2. Our research conformed to the Helsinki
declaration and local legislations, and has been approved
by the AlAin Medical District Human Research Ethics
Committee at the Faculty of Medicine and Health Sci-
ences, University of United Arab Emirates, under ethical
permit no. AAMD/HREC 08/15. All participating patients
signed consent forms after receiving a verbal and written
information sheet.
Blood samples and cancer tissues collection
A total of 351 peripheral blood samples were collected
from 117 de novo cancer patients with a mean age of
54 years (18–89 years). Sampled tumors included: 20
gastric carcinoma (CA), 19 nasopharyngeal cancer, 13
ovarian cancer, 12 lung cancer, 9 pancreatic CA, 9
prostate CA, 9 squamous cell CA, 6 anal canal cancer,
6 germ cell tumors, 4 oral cavity cancer, 4 uterus sar-
coma, 3 urinary bladder CA, 2 glioblastoma, and 1
case of Ewing’s sarcoma. Sampling was conducted on
three occasions starting at 4–5 weeks prior to the first
chemotherapy session (pre-treatment sample) to serve
as a baseline, and two consecutive draws at 12-week
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samples (post-treatment-1) were used to investigate
the presence of MSI and LOH, and second post-
treatment samples (post-treatment-2) were used to de-
termine the persistence of the initial findings. One
hundred eighty blood samples were collected from 60
healthy individuals who had never reported symptoms
relevant to any neoplastic case. Sampling of the
reference group followed the same protocol applied
to patients. Samples of 196 cancer tissues resected
from patients were collected from the pathology de-
partment for MMR protein expression analysis using
immunohistochemistry.
DNA extraction and LOH and MSI analysis
Genomic DNA was extracted from whole blood using 200-
μl blood DNA kits, on a Biorobot EZ1 workstation (Qiagen
Inc, Valencia, California, USA,). DNA yield was quantified
using absorbance at A260 on a Beckman Coulter DU 650
spectrophotometer with special applications for nucleic
acid quantification (Beckman Coulter Inc, Brea, California,
USA). DNA purity, checked on A260/A280 absorbance, aver-
aged 1.72.
Single and multiplex polymerase chain reactions (PCR)
were conducted to amplify 10 loci (Bat-40, AFM093xh3,
Bat-25, APC, Mfd15, Mfd41, Mfd28, Bat-26, Tp53-Alu
and TP53.PCR15) on chromosomes 1, 2, 4, 5, 10, and 17.
Fluorescently labeled primers were used to amplify the
selected loci as previously described [58], and are detailed
in Additional file 3: Table S2. Amplification reactions were
conducted in 10 μl reaction volume of 1× Gold Amplitaq
Master Mix (Applied Biosystems, Carlsbad, California,
USA) with the addition of 80 ng purified genomic DNA,
and adjusted to a final primer concentration of 0.4 μM.
Cycling conditions were as follows: initial denaturation at
95°C for 5 minutes; 29 cycles of 94°C for 45 sec, 50–62°C
for 30 sec, and 72°C for 50 seconds; and a final 50 minute
extension at 70°C. PCR products were denatured in Hi-Di
formamide, pooled with LIZ 500 GS internal molecular
weight control and loaded on an ABI 3130 genetic
analyzer (Applied Biosystems, Carlsbad, California, USA).
Fragments were measured and compared using Gene-
Mapper software Version 4 (Applied Biosystems, Carlsbad,
California, USA). GeneScan data were obtained using a
minimum peak detection limit of 50 relative fluorescent
units and applying the local Southern size calling method.
MSI irregularities were demonstrated by comparisons
between the numbers and allele arrangements of pre-
treatment and post-treatment samples. Specifically, new
peak addition or the presence of novel alleles indicated
MSI [59], whereas LOH was indicated when the peak
height of one of the two heterozygote alleles was reduced
by at least 35% [60,61]. GeneMapper Software Version 4
was used to calculate LOH.MMR analyses
Archived tissue samples were available from 101 pa-
tients. In three cases, the available tissues were not
sufficient for the procedure. Two specimens from each
patient were tested for MMR protein expression (pre
and post-treatment). The 196 cancer tissues were embed-
ded in paraffin blocks for MMR protein expression ana-
lysis. The TP-125 HLX Ultravision Plus Anti-Polyvalent
HRP detection system (Lab Vision, Fremont, California,
USA) using specific monoclonal antibodies for hMLH1,
hMSH2, hMSH6, hPMS2 and P53 (Cell Marque, Rocklin,
California , USA, California) was used in the staining pro-
cedure. Results were marked as positive when 10% or
more of cells stained positively (nuclear stain). Healthy tis-
sue from each patient and the standard controls supplied
by the manufacturer were used as internal controls.
Statistical analyses
Confidence intervals were calculated at the 95% and 99%
levels. Fisher’s exact test and Chi Square were used
for statistical analyses with the SPSS statistical analysis
package. Additionally, an inter-rater reliability test using
Cohen’s kappa coefficient was used to measure correlation
between the MSI and LOH results and low MMR protein
expression [62].
Additional files
Additional file 1: Figure S1. Emergence of a novel allele of 162
nucleotides following the loss of heterozygosity in alleles 109 and 118 of APC.
Additional file 2: Figure S2. Positive correlation between rates of MSI
and LOH and the patient’s age. As patient’s age increases, the incidence
of MSI and LOH appears to increase.
Additional file 3: Table S1. Frequently used chemotherapy treatments
in managing the sampled solid tumors in the current study. Table S2.
The specific characteristics of the analyzed microsatellite markers.
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